194 related articles for article (PubMed ID: 33293375)
1. Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans.
Stadlbauer A; Kinfe TM; Eyüpoglu I; Zimmermann M; Kitzwögerer M; Podar K; Buchfelder M; Heinz G; Oberndorfer S; Marhold F
Clin Cancer Res; 2021 Mar; 27(6):1641-1649. PubMed ID: 33293375
[TBL] [Abstract][Full Text] [Related]
2. Vascular architecture mapping for early detection of glioblastoma recurrence.
Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia and Microvascular Alterations Are Early Predictors of IDH-Mutated Anaplastic Glioma Recurrence.
Stadlbauer A; Oberndorfer S; Heinz G; Zimmermann M; Kinfe TM; Doerfler A; Buchfelder M; Kremenevski N; Marhold F
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918764
[TBL] [Abstract][Full Text] [Related]
4. From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence.
Zygogianni A; Protopapa M; Kougioumtzopoulou A; Simopoulou F; Nikoloudi S; Kouloulias V
Clin Transl Oncol; 2018 Aug; 20(8):989-1003. PubMed ID: 29335830
[TBL] [Abstract][Full Text] [Related]
5. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
Hu LS; Eschbacher JM; Heiserman JE; Dueck AC; Shapiro WR; Liu S; Karis JP; Smith KA; Coons SW; Nakaji P; Spetzler RF; Feuerstein BG; Debbins J; Baxter LC
Neuro Oncol; 2012 Jul; 14(7):919-30. PubMed ID: 22561797
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and neuroimaging findings in 12 cases of recurrent glioblastoma with communicating hydrocephalus.
Onuma K; Ishikawa E; Matsuda M; Hirata K; Osuka S; Yamamoto T; Masumoto T; Zaboronok A; Matsumura A
Neurol Med Chir (Tokyo); 2013; 53(7):474-81. PubMed ID: 23883558
[TBL] [Abstract][Full Text] [Related]
7. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.
Yao J; Tan CHP; Schlossman J; Chakhoyan A; Raymond C; Pope WB; Salamon N; Lai A; Ji M; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2019 May; 142(3):587-595. PubMed ID: 30806888
[TBL] [Abstract][Full Text] [Related]
8. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
Vymazal J; Wong ET
Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
[TBL] [Abstract][Full Text] [Related]
9. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis.
Rong Y; Durden DL; Van Meir EG; Brat DJ
J Neuropathol Exp Neurol; 2006 Jun; 65(6):529-39. PubMed ID: 16783163
[TBL] [Abstract][Full Text] [Related]
10. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.
Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB
J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699
[TBL] [Abstract][Full Text] [Related]
11. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
[TBL] [Abstract][Full Text] [Related]
12. Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and
Huang S; Michalek JE; Reardon DA; Wen PY; Floyd JR; Fox PT; Clarke GD; Jerabek PA; Schmainda KM; Muzi M; Hyun H; Lee EQ; Brenner AJ
Sci Rep; 2021 Apr; 11(1):7632. PubMed ID: 33828310
[TBL] [Abstract][Full Text] [Related]
13. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
[TBL] [Abstract][Full Text] [Related]
14. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
15. Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.
Khalifa J; Tensaouti F; Chaltiel L; Lotterie JA; Catalaa I; Sunyach MP; Ibarrola D; Noël G; Truc G; Walker P; Magné N; Charissoux M; Ken S; Peran P; Berry I; Moyal EC; Laprie A
Eur Radiol; 2016 Nov; 26(11):4194-4203. PubMed ID: 26843012
[TBL] [Abstract][Full Text] [Related]
16. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
[TBL] [Abstract][Full Text] [Related]
17. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
[TBL] [Abstract][Full Text] [Related]
19. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
Suchorska B; Weller M; Tabatabai G; Senft C; Hau P; Sabel MC; Herrlinger U; Ketter R; Schlegel U; Marosi C; Reifenberger G; Wick W; Tonn JC; Wirsching HG
Neuro Oncol; 2016 Apr; 18(4):549-56. PubMed ID: 26823503
[TBL] [Abstract][Full Text] [Related]
20. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model.
Veeravagu A; Hou LC; Hsu AR; Cai W; Greve JM; Chen X; Tse V
Neurol Res; 2008 Nov; 30(9):952-9. PubMed ID: 18662497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
